These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 18985036)

  • 1. Human thyroid tumours, the puzzling lessons from E7 and RET/PTC3 transgenic mice.
    Jin L; Burniat A; Dumont JE; Miot F; Corvilain B; Franc B
    Br J Cancer; 2008 Dec; 99(11):1874-83. PubMed ID: 18985036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.
    Burniat A; Jin L; Detours V; Driessens N; Goffard JC; Santoro M; Rothstein J; Dumont JE; Miot F; Corvilain B
    Endocrinology; 2008 Oct; 149(10):5107-17. PubMed ID: 18583418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papilloma virus 16 E7 oncogene does not cooperate with RET/PTC 3 oncogene in the neoplastic transformation of thyroid cells in transgenic mice.
    Portella G; Borselli C; Santoro M; Gerbasio D; D'Armiento MR; Dumont JE; Ledent C; Rothstein JL; Vecchio G; Fusco A
    Oncol Res; 2001; 12(8):347-54. PubMed ID: 11589306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of connexin32 deletion on E7 or RET/PTC3 oncogene-driven growth and neoplastic transformation of the thyroid gland.
    Prost G; Bernier-Valentin F; Croset M; Rousset B
    Endocr Relat Cancer; 2009 Sep; 16(3):873-84. PubMed ID: 19509066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histopathological changes induced by selective inactivation of menin on the thyroid gland in RET÷PTC3 and E7 transgenic mice. A study of 77 cases.
    Căpraru OM; Berger N; Gadot N; Decaussin-Petrucci M; Zhang C; Borda A; Szilágyi T; Borson-Chazot F; Selmi-Ruby S
    Rom J Morphol Embryol; 2016; 57(1):91-8. PubMed ID: 27151693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling.
    Mesa C; Mirza M; Mitsutake N; Sartor M; Medvedovic M; Tomlinson C; Knauf JA; Weber GF; Fagin JA
    Cancer Res; 2006 Jul; 66(13):6521-9. PubMed ID: 16818623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcript level modulates the inherent oncogenicity of RET/PTC oncoproteins.
    Richardson DS; Gujral TS; Peng S; Asa SL; Mulligan LM
    Cancer Res; 2009 Jun; 69(11):4861-9. PubMed ID: 19487296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High iodine concentration attenuates RET/PTC3 oncogene activation in thyroid follicular cells.
    Fiore AP; Fuziwara CS; Kimura ET
    Thyroid; 2009 Nov; 19(11):1249-56. PubMed ID: 19725779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 24 is induced by the RET/PTC3 oncoprotein and is an autocrine growth factor for epithelial cells.
    Shinohara S; Rothstein JL
    Oncogene; 2004 Sep; 23(45):7571-9. PubMed ID: 15326486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of siRNA on RET/PTC3 junction oncogene in papillary thyroid carcinoma: from molecular and cellular studies to preclinical investigations.
    Ali HM; Urbinati G; Chapuis H; Desmaele D; Bertrand JR; Couvreur P; Massaad-Massade L
    PLoS One; 2014; 9(4):e95964. PubMed ID: 24759995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRAFV600E and RET/PTC Promote Proliferation and Migration of Papillary Thyroid Carcinoma Cells In Vitro by Regulating Nuclear Factor-κB.
    Zhou D; Li Z; Bai X
    Med Sci Monit; 2017 Nov; 23():5321-5329. PubMed ID: 29117154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
    Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
    Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Papillary thyroid carcinoma: 6 cases from 2 families with associated lymphocytic thyroiditis harbouring RET/PTC rearrangements.
    Mechler C; Bounacer A; Suarez H; Saint Frison M; Magois C; Aillet G; Gaulier A
    Br J Cancer; 2001 Dec; 85(12):1831-7. PubMed ID: 11747322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET/PTC-induced gene expression in thyroid PCCL3 cells reveals early activation of genes involved in regulation of the immune response.
    Puxeddu E; Knauf JA; Sartor MA; Mitsutake N; Smith EP; Medvedovic M; Tomlinson CR; Moretti S; Fagin JA
    Endocr Relat Cancer; 2005 Jun; 12(2):319-34. PubMed ID: 15947106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The oncogenic activity of RET point mutants for follicular thyroid cells may account for the occurrence of papillary thyroid carcinoma in patients affected by familial medullary thyroid carcinoma.
    Melillo RM; Cirafici AM; De Falco V; Bellantoni M; Chiappetta G; Fusco A; Carlomagno F; Picascia A; Tramontano D; Tallini G; Santoro M
    Am J Pathol; 2004 Aug; 165(2):511-21. PubMed ID: 15277225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of RET/PTC mutations in papillary thyroid cancers in Turkish population and its relation between tumor histopathology and prognostic factors.
    Erdoğan M; Berdeli A; Karadeniz M; Ertan Y; Cetinkalp S; Saygili F; Tuncyurek M; Yilmaz C; Tuzun M; Kabalak T; Uluer H; Ozgen AG
    Exp Clin Endocrinol Diabetes; 2008 Apr; 116(4):225-30. PubMed ID: 18393128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of differentially expressed genes in papillary thyroid carcinomas with and without rearrangements of the tyrosine kinase receptors RET and/or NTRK1.
    Musholt TJ; Brehm C; Hanack J; von Wasielewski R; Musholt PB
    J Surg Res; 2006 Mar; 131(1):15-25. PubMed ID: 16256137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
    Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
    Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential patterns of cell cycle regulatory proteins expression in transgenic models of thyroid tumours.
    Coppée F; Depoortere F; Bartek J; Ledent C; Parmentier M; Dumont JE
    Oncogene; 1998 Aug; 17(5):631-41. PubMed ID: 9704929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.